The association between drug shortages and prices across 74 countries: uncovering global access inequities.

backgroundDrug shortages are a global concern that poses risks to clinical care and health systems. Lower prices and market pressures are often cited as drivers of drug shortages; thus, a commonly proposed policy lever is to increase drug prices. However, global evidence to evaluate the association between shortages and prices is lacking. This research aims to fill the gap by examining the global markets of drug shortages.

methodWe included 25 global shortage markets by reviewing publications on drug shortages from 2013 to 2023. We used quarterly pharmaceutical sales data across 74 countries/regions from the IQVIA MIDAS quarterly sales volume data database from Q3 2011 to Q3 2022. Our outcome of interest was shortage intensity, defined as the drug shortage duration between its onset and the end of meaningful shortages. To assess the impact of price on the occurrence and intensity of shortages, we used zero-inflated negative binomial regression, with price as the independent factor and included gross domestic product (GDP) per capita and the number of manufacturers as covariates. P values less than a Bonferroni-corrected significance level (0.00625) were considered statistically significant.

resultsOut of 1096 subjects (each representing a drug market in a specific country), 65% (712 subjects) experienced meaningful shortages with a median shortage intensity of 10 quarters. We found price was not a significant predictor of either shortage odds (p=0.044) or intensity (p=0.066). Factors significantly associated with increased odds of a non-shortage occurrence included a unit increase in GDP per capita (adjusted OR (aOR): 1.707, 95% CI 1.428 to 2.040) and in the number of manufacturers (aOR: 4.038, 95% CI 3.045 to 5.354), corresponding to 70.7% and 303.8% higher odds, respectively. A unit increase in GDP per capita was significantly associated with a 10.4% decrease (adjusted rate ratios: 0.896, 95% CI 0.834 to 0.962) in the duration of shortage intensity.

conclusionOur study reveals global inequities in the impact of drug shortages, with countries with lower GDP per capita disproportionately affected. Persistent shortages of essential medications have been observed worldwide over the past decade, but are not evenly distributed across countries. Collectively, our findings suggest the need to consider creative and alternative policy strategies beyond pricing to address both critical drug shortages and global inequities in shortage experiences.